DUBLIN--(BUSINESS WIRE)--The "Myocardial Infarction - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Myocardial Infarction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 15, 8, 53, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 20 and 4 molecules, respectively.
Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
- Actinogen Medical Ltd
- Angion Biomedica Corp
- Applied Therapeutics Inc
- Athera Biotechnologies AB
- Athersys Inc
- Bharat Biotech Ltd
- BioCardia Inc
- Biscayne Pharmaceuticals Inc
- Cadila Healthcare Ltd
- Cardiol Therapeutics Inc
- Celixir Ltd
- CellProthera SAS
- CFM Pharma Holding BV
- Cynata Therapeutics Ltd
- Diffusion Pharmaceuticals Inc
- Evotec AG
- EyeGene Inc
- Faraday Pharmaceuticals Inc
- Hemostemix Inc
- HUYA Bioscience International LLC
- Idorsia Pharmaceutical Ltd
- InCarda Therapeutics Inc
- Inotrem SA
- K-Stemcell Co Ltd
- Laboratoires Pierre Fabre SA
- Lee's Pharmaceutical Holdings Ltd
- LG Chem Ltd
- Lonestar Heart Inc
- Mesoblast Ltd
- MimeTech Srl
- New World Laboratories Inc
- Novartis AG
- NuvOx Pharma LLC
- OMEICOS Therapeutics GmbH
- Opsona Therapeutics Ltd
- Otsuka Holdings Co Ltd
- Quark Pharmaceuticals Inc
- Reata Pharmaceuticals Inc
- Recardio GmbH
- Reliance Life Sciences Pvt Ltd
- Rubicon Biotechnology Inc
- Silver Creek Pharmaceuticals Inc
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Co Ltd
- Thrombolytic Science International LLC
- Vicore Pharma AB
- ViroMed Co Ltd
- XBiotech Inc
- YiChang Humanwell Pharmaceutical Co Ltd
- Yuyu Pharma Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qcxxfq/myocardial?w=4
